Catching Up On Biopharma’s Recent Move
Research - The recovery is slowly underway in the land of biotech, and these equities are getting a lift from Pfizer's (PFE) planned merger with Allergan (AGN), announced Monday.
Read nowSearch Results for gene therapy
Filling the Void in Beta Thalassemia
Research - Bellicum Pharmaceuticals (BLCM) after the bell this evening reported third quarter earnings, but more importantly noted that four pediatric beta-thalassemia patients who underwent HSCT followed by BPX-501 modified T cells are transfusion-free.
Premium
Biotech Equities Are Finally Making Up Lost Ground
Insights - The biotech sector has taken a meaningful step towards making up lost ground. After consolidating between $290 and $320 for the last month, the NASDAQ … Continue Reading
Read now
Can Bellicum’s ASH Data Change the Story?
Research - Bellicum is a cell therapy developer with a pipeline of early therapeutics, including the now-ubiquitous chimeric antigen receptor T cell candidates (a la Juno Therapeutics (JUNO) and Kite (KITE)) and T cell receptor (TCR) candidates, neither of which will enter the clinic until next year.
Premium
Bluebird Bio Drops on Patient “Relapse” and Other Biotech Updates
Research - Shares of bluebird bio (BLUE) tumbled 15% mid-day when the company said at a medical conference that a beta-thalassemia patient who received Lentiglobin’s predecessor therapeutic … Continue Reading
Premium
Cempra’s Phase 3 Hit Its Primary Endpoints, But Not Without Caveats
Research - Positive top-line results from SOLITAIRE-IV, with some confounding safety outcomes, had Cempra Inc (CEMP) trading down on Friday morning by 25%.
Premium
Neurocrine Chalks Up a Win With Latest Clinical Trial
Insights - Teva Pharmaceuticals (TEVA) purchased Auspex Pharmaceuticals this spring for $3.5 billion, primarily for access to the developmental SD-809 (deutetrabenazine), which was in mid-stage studies for the treatment of chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. But the larger pharma company has a competitor nipping at its heels.
Read now